Neil D. Gross, MD, on Clinical Implications of Recent Findings on Cemiplimab in Cutaneous Squamous Cell Carcinoma

Posted: Thursday, September 15, 2022

Neil D. Gross, MD, of The University of Texas MD Anderson Cancer Center, discusses what it could mean, going forward, for patients with stage II–IV (M0) cutaneous squamous cell carcinoma who may benefit from neoadjuvant cemiplimab-rwlc, which was shown to be active in a phase II study and may enable function-preserving surgery in some cases.